DM, I like your response/post. drugmanrx Re: hotmeat

New Post Public Reply Private Reply Replies (0) Message Board
Wallstreet1234
151
DM, I like your response/post.

drugmanrx
Re: hotmeat post# 83536
Monday, July 28, 2025 3:43:16 PM
Post# of 83540


Oh so you think it is silly behavior to be concern that our CEO has RS his shareholders stock by 4000 to 1 and at the same time turn his company into a shell while simultaneous starting a private company, with the same personnel and business plan as his public company, that HE REFUSED to say it has a relationship with SNPW..

Interesting.

I capitalized when the PPS rose, SNPW CEO was not running a shell, SNPW CEO was not Solray Inc CEO, a direct operating competitor, SNPW was not a self declaring shelll and SNPW CEO kept telling his shareholders that a RS was not going to happen or even be necessary..

What info are you referring to " these requests for info that are not, or not yet available"

Solray INC is available. They have their own website and list their CEO as Nicholas Campanella. The only person that could authorized listing Nicholas Campanella as CEO of Solray Inc, is Nicholas Campanella CEO of SNPW. .

Sun Pacific Power India info was available, they are the ones that said the were under Sun Pacific Power USA and that they completed 400 jobs.. The only one that could allow SPPI to put SPPC name on its website is the CEO of SPPC Nicholas Campanella.

The SEC filings were available, the OTC filings are available yet show no revenue coming from SPPC from it former store even though they said they were selling products or for work SPPC claimed it did for FoxEss and GEP. The only person that signs off on the filings is Nicholas Campanella.

All information on line whether it be Solray Inc, Sun Pacific Power India being a part of Sun Pacific Power USA, Sun Pacific Power India completing 400 jobs, SPPI testimonials of completed jobs and what goes in the filings were approved and made public by Nicholas Campanella (NO ONE ELSE), those issues need to be addressed.

One can "wait and see" while at the same time question certain public information that comes directly from SNPW CEO Nicholas Campanella.


In response to this illogical post.

hotmeat
Re: drugmanrx post# 83527
Monday, July 28, 2025 9:56:12 AM
Post# of 83540
TBH, you seem to be emulating, to a much lesser extent, the silly behaviour of the jokers that were pestering the company and its affiliates, and yet wonder why your repeated contacts for info are being ignored???

Most here, it seems, have adopted the "wait and see" option because, IMO, these requests for info that are not, or not yet available, makes absolutely no sense whatsoever.

The fact that you admitted to capitalizing greatly when the PPS rose should at least provide you with the ability to adopt the same, or similar modus operandi as most shareholders whom i'm sure are also eager to see what becomes of SunP.


Adopting a wait and see after a 4k reverse, $8k dollars reported in bank account last filing, zero revenue, $3.7m in liabilities and listed as a shell company. SMH Me no think so.

Sun Pacific Holding Corp. (SNPW) Stock Research Links

SNPW Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Home Insurance Gaps: Risky Assumptions Uncovered

Updated Category News Views 53

Unseen Threats to Homeownership Safety Liability gaps in insurance are like those stubborn stains on the carpet you keep missing—nearly invisible until you're flat on your face. In Alpharetta and Fulton County, homes aren't as secure from financial pitfalls as their charming façades suggest. So, what's the danger that folks are glossing over here? Hidden Dangers of...

Continue Reading
Pathalys' Phase 3 Data Shows Promise for CKD Drug

Updated Category News Views 46

A Glimpse at Pathalys Pharma's Recent Win This is some groundbreaking stuff emerging from Pathalys Pharma. Their investigational drug, upacicalcet, has just clinched a significant victory in two crucial Phase 3 trials - PATH-1 and PATH-2 - aimed at treating Secondary Hyperparathyroidism (SHPT) in patients with end-stage kidney disease undergoing hemodialysis. With SHPT...

Continue Reading
Enigmata Innovates AI Security with Finovifi Tie-Up

Updated Category News Views 133

Emerging AI Risks and Protective Measures AI in financial spaces is like walking a tightrope, there's potential but caution is crucial. Enter Enigmata, diving headfirst into this arena by shaking hands with the Finovifi Marketplace. Their aim? To bolster AI's promise without letting sensitive data slip through the cracks. Sentinel: A New Guard for Sensitive Data Let's not...

Continue Reading
Northern Virginia's Housing Inventory Surges Despite Market Pressures

Updated Category News Views 96

Unexpected Surge in Northern Virginia's Inventory Walking around Fairfax these days, you might feel like you're in a time warp, especially if you're tracking the housing market. See, while the rest of the country's housing market groans under sluggish sales and creeping prices, Northern Virginia's doing a dance of its own. Inventory's ballooning faster than a parade...

Continue Reading
Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Updated Category News Views 134

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Continue Reading
Monterey Desalination Project: Costs, Challenges & Future

Updated Category News Views 19

Water Woes Dragging on in Monterey? Alright, let's dive into the nitty-gritty of this water supply saga in the Monterey Peninsula. If you're wondering why California American Water is hustling so hard, it's because the taps around here ain't running like they should. This mess has been stretching on for ages, with everyone thirsty for a sustainable answer. The Cost of...

Continue Reading
Empire Steak House Expands to Delray Beach

Updated Category News Views 57

Steakhouse Kings Bring New York Flavors to Florida When you're talking about steak, the Empire Steak House name carries some serious heft. This isn't just another restaurant chain cashing in on prime cuts; it's a family legacy over 21 years in the making. The Sinanaj Brothers, who honed their skills at Peter Luger in New York, are moving their empire south, landing a...

Continue Reading
CapCut's AI Tools Reshape Video Content Creation

Updated Category News Views 31

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...

Continue Reading
Callender Bowlin's Legal Eagles Soar in Texas 2026

Updated Category News Views 4

The Spotlight on CB Trial's Legal Titans Roll the dice, folks—who stands up in Texas’ legal playground? It's Callender Bowlin, PLLC's hotshots again securing their hallmark in the 2026 Texas Super Lawyers gauntlet. This ain’t their first rodeo, either. Founding partners Mark Callender and Josh Bowlin—names synonymous with high-stakes litigation—continue to bask...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 16

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Show Strong Interest in Micron Technology's Future

Updated Category News Views 116

Investor Interest in Micron Technology Investors looking for promising opportunities are increasingly focused on Micron Technology. This semiconductor giant has caught the attention of many, especially with its substantial trading activity. Understanding the Current Options Activity Recent data has revealed notable trades in Micron Technology's options. The presence of...

Continue Reading
Dundee Precious Metals Confirms Dividend Declaration for Shareholders

Updated Category News Views 144

Dundee Precious Metals Confirms Dividend Announcement Dundee Precious Metals Inc. (TSX: DPM) has announced a significant update regarding its financial strategy. The Board of Directors has formally declared a third-quarter dividend amounting to US$0.04 per common share. This decision reflects the company's ongoing commitment to providing value to its shareholders while...

Continue Reading
Praesidian Capital Celebrates Successful E-commerce Exit Strategy

Updated Category News Views 127

Praesidian Capital Celebrates Successful E-commerce Exit Strategy Recently, Praesidian Capital, a private equity firm, made headlines with its successful exit from a tech-enabled e-commerce consumer products distribution business. This move showcases the firm's strategic prowess in identifying and monetizing valuable investment opportunities in a dynamic market. Insights...

Continue Reading
CW Bancorp Announces Quarterly Dividend for Shareholders

Updated Category News Views 215

CW Bancorp Declares a Refreshing Quarterly Dividend CW BANCORP (OTCQX: CWBK), the parent company of CommerceWest Bank, recently announced the approval of a quarterly cash dividend by its Board of Directors. This step signifies the company's ongoing dedication to maximizing shareholder value. The Board declared a cash dividend of $0.23 per common share, illustrating the...

Continue Reading
Investors Stand to Gain from Novo Nordisk A/S Class Action Suit

Updated Category News Views 188

Understanding the Opportunity in Novo Nordisk Class Action The recent developments surrounding Novo Nordisk A/S (NYSE: NVO) present a significant opportunity for investors to lead a class action lawsuit against the company. This initiative arises from allegations of securities fraud that may have impacted stockholder interests. The law firm managing this case assures that...

Continue Reading